Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
Heart Failure, Congestive
About this trial
This is an interventional diagnostic trial for Heart Failure, Congestive focused on measuring Heart Failure, nuclear cardiology, sympathetic innervation, 123I-mIBG
Eligibility Criteria
Inclusion Criteria: Study subjects must be adults with an established diagnosis of heart failure (New York Heart Association Class II or III) and reduced left ventricular ejection fraction (LVEF) (≤ 35%) or be healthy volunteers without heart disease. Exclusion Criteria: Healthy volunteers are not eligible if they have a history diabetes mellitus, signs/symptoms of neurological disease (eg, Parkinson's Disease, multiple system atrophy, Parkinsonian syndromes), or other diseases known to affect the sympathetic nervous system. Subjects with New York Heart Association Class I or IV heart failure are not eligible.
Sites / Locations
- GE Healthcare
Arms of the Study
Arm 1
Experimental
123I-mIBG (meta-iodobenzylquanidine
Single dose